Predictive Factors for Visual Outcome after Treatment for Myopic Choroidal Neovascularization.
10.3341/jkos.2013.54.4.610
- Author:
Ha Na OH
1
;
Joo Eun LEE
;
Hyun Woong KIM
;
Il Han YUN
Author Information
1. Department of Ophthalmology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea. ihyun@inje.ac.kr
- Publication Type:Original Article
- Keywords:
Anti-VEGF;
Bevacizumab;
Myopic CNV;
PDT;
Ranibizumab
- MeSH:
Antibodies, Monoclonal, Humanized;
Choroid;
Choroidal Neovascularization;
Endothelial Growth Factors;
Eye;
Humans;
Linear Models;
Medical Records;
Photochemotherapy;
Retrospective Studies;
Triazenes;
Visual Acuity;
Bevacizumab;
Ranibizumab
- From:Journal of the Korean Ophthalmological Society
2013;54(4):610-617
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To determine predictive factors associated with visual outcome after treatment for myopic choroidal neovascularization (mCNV). METHODS: Medical records of the patients who underwent photodynamic therapy (PDT), intravitreal anti-vascular endothelial growth factor (Anti-VEGF) injection, or combination therapy of PDT and Anti-VEGF for myopic CNV, and followed up for more than a year, were reviewed retrospectively. Multiple linear regression analyses were performed to evaluate the predictive factors significantly associated with the visual outcome at 1 year after the treatment. RESULTS: Mean best-corrected visual acuity (BCVA) of 45 eyes of 45 patients showed statistically significant improvement 1 year after the treatment with a mean of 3.5 line improvement (p < 0.01, Wilcoxon signed rank test). Age, 1-month BCVA after treatment and treatment type appeared to be associated with the 1-year visual outcome after treatment for mCNV (p = 0.033, p < 0.001, and p = 0.044, respectively, multivariate linear regression analysis). CONCLUSIONS: Younger age (less than 40 years), better 1-month BCVA after treatment, intravitreal Anti-VEGF monotherapy were associated with improved visual outcome after treatment for mCNV. In particular, 1-month BCVA after treatment is a useful indicator to predict therapeutic response after treatment for mCNV.
